NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Nuvation Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.48+0.03 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Nuvation Bio Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| License [Member] | $38.24M | $7.87M | 60.8% | +385.7% |
| Product Revenue [Member] | $24.70M | – | 39.3% | – |
| Product [Member] | $24.66M | $0 | 39.2% | – |
| Research And Development Service Revenue [Member] | – | $5.79M | – | – |
| License revenue | – | $2.09M | – | – |
By region
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Japan | $28.83M | $2.73M | 45.8% | +957.6% |
| United States | $24.66M | $0 | 39.2% | – |
| China | $9.41M | $5.15M | 15.0% | +82.8% |
From the segment and revenue-disaggregation notes of Nuvation Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.